These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 36719097)

  • 81. Finerenone Added to RAS/SGLT2 Blockade for CKD in Alport Syndrome. Results of a Randomized Controlled Trial with Col4a3-/- Mice.
    Zhu Z; Rosenkranz KAT; Kusunoki Y; Li C; Klaus M; Gross O; Angelotti ML; Antonelli G; Cirillo L; Romagnani P; Bouteldja N; Sadr AV; Bülow RD; Boor P; Anders HJ
    J Am Soc Nephrol; 2023 Sep; 34(9):1513-1520. PubMed ID: 37428955
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Clinical implications and guidelines for CKD in type 2 diabetes.
    Zhang RM; Persson F; McGill JB; Rossing P
    Nephrol Dial Transplant; 2023 Feb; 38(3):542-550. PubMed ID: 36264310
    [TBL] [Abstract][Full Text] [Related]  

  • 83. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics.
    Wheeler DC; Stefansson BV; Batiushin M; Bilchenko O; Cherney DZI; Chertow GM; Douthat W; Dwyer JP; Escudero E; Pecoits-Filho R; Furuland H; Górriz JL; Greene T; Haller H; Hou FF; Kang SW; Isidto R; Khullar D; Mark PB; McMurray JJV; Kashihara N; Nowicki M; Persson F; Correa-Rotter R; Rossing P; Toto RD; Umanath K; Van Bui P; Wittmann I; Lindberg M; Sjöström CD; Langkilde AM; Heerspink HJL
    Nephrol Dial Transplant; 2020 Oct; 35(10):1700-1711. PubMed ID: 32862232
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Cost-effectiveness of Finerenone in Addition to Standard of Care for Patients with Chronic Kidney Disease and Type 2 Diabetes in China.
    Ming J; Hong G; Xu Y; Mernagh P; Pochopień M; Li H
    Adv Ther; 2024 Aug; 41(8):3138-3158. PubMed ID: 38880821
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Emerging Preventive Strategies in Chronic Kidney Disease: Recent Evidence and Gaps in Knowledge.
    Pradhan N; Dobre M
    Curr Atheroscler Rep; 2023 Dec; 25(12):1047-1058. PubMed ID: 38038822
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Effects of Finerenone on Cardiovascular and Chronic Kidney Diseases: A New Weapon against Cardiorenal Morbidity and Mortality-A Comprehensive Review.
    Piccirillo F; Liporace P; Nusca A; Nafisio V; Corlianò A; Magarò F; Antonelli Incalzi R; Ussia GP; Grigioni F
    J Cardiovasc Dev Dis; 2023 May; 10(6):. PubMed ID: 37367401
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Finerenone in patients across the spectrum of chronic kidney disease and type 2 diabetes by glucagon-like peptide-1 receptor agonist use.
    Rossing P; Agarwal R; Anker SD; Filippatos G; Pitt B; Ruilope LM; Fonseca V; Umpierrez GE; Caramori ML; Joseph A; Lambelet M; Lawatscheck R; Bakris GL;
    Diabetes Obes Metab; 2023 Feb; 25(2):407-416. PubMed ID: 36193847
    [TBL] [Abstract][Full Text] [Related]  

  • 88. New Paradigms for CKD Management in Patients With T2D.
    Neumiller JJ; Brunton SA
    J Fam Pract; 2023 Jul; 72(6 Suppl):S37-S42. PubMed ID: 37549415
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes.
    Filippatos G; Anker SD; Agarwal R; Pitt B; Ruilope LM; Rossing P; Kolkhof P; Schloemer P; Tornus I; Joseph A; Bakris GL;
    Circulation; 2021 Feb; 143(6):540-552. PubMed ID: 33198491
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Design and rationale of FINE-REAL: A prospective study of finerenone in clinical practice.
    Desai NR; Navaneethan SD; Nicholas SB; Pantalone KM; Wanner C; Hamacher S; Gay A; Wheeler DC
    J Diabetes Complications; 2023 Apr; 37(4):108411. PubMed ID: 36857997
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Clinical perspective-evolving evidence of mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes.
    Rossing P
    Kidney Int Suppl (2011); 2022 Apr; 12(1):27-35. PubMed ID: 35529090
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Finerenone cardiovascular and kidney outcomes by age and sex: FIDELITY post hoc analysis of two phase 3, multicentre, double-blind trials.
    Bansal S; Canziani MEF; Birne R; Anker SD; Bakris GL; Filippatos G; Rossing P; Ruilope LM; Farjat AE; Kolkhof P; Lage A; Brinker M; Pitt B
    BMJ Open; 2024 Mar; 14(3):e076444. PubMed ID: 38508632
    [TBL] [Abstract][Full Text] [Related]  

  • 93. An analysis of DPV and DIVE registry patients with chronic kidney disease according to the finerenone phase III clinical trial selection criteria.
    Bramlage P; Lanzinger S; Mühldorfer S; Milek K; Gillessen A; Veith R; Ohde T; Danne T; Holl RW; Seufert J
    Cardiovasc Diabetol; 2023 May; 22(1):108. PubMed ID: 37158855
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside.
    Kolkhof P; Jaisser F; Kim SY; Filippatos G; Nowack C; Pitt B
    Handb Exp Pharmacol; 2017; 243():271-305. PubMed ID: 27830348
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Cardiovascular and Renal Outcomes with Finerenone, a Selective Mineralocorticoid Receptor Antagonist.
    Palanisamy S; Funes Hernandez M; Chang TI; Mahaffey KW
    Cardiol Ther; 2022 Sep; 11(3):337-354. PubMed ID: 35737275
    [TBL] [Abstract][Full Text] [Related]  

  • 96. The significance of finerenone as a novel therapeutic option in diabetic kidney disease: a scoping review with emphasis on cardiorenal outcomes of the finerenone phase 3 trials.
    Arici M; Altun B; Araz M; Atmaca A; Demir T; Ecder T; Guz G; Gogas Yavuz D; Yildiz A; Yilmaz T
    Front Med (Lausanne); 2024; 11():1384454. PubMed ID: 38947237
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Direct Blood Pressure-Independent Anti-Fibrotic Effects by the Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone in Progressive Models of Kidney Fibrosis.
    Droebner K; Pavkovic M; Grundmann M; Hartmann E; Goea L; Nordlohne J; Klar J; Eitner F; Kolkhof P
    Am J Nephrol; 2021; 52(7):588-601. PubMed ID: 34515038
    [TBL] [Abstract][Full Text] [Related]  

  • 98. FINE-CKD model to evaluate economic value of finerenone in patients with chronic kidney disease and type 2 diabetes.
    Pochopień MT; Cherney DZI; Folkerts K; Levy P; Millier A; Morris S; Roy-Chaudhury P; Sullivan SD; Mernagh P
    Am J Manag Care; 2021 Dec; 27(20 Suppl):S375-S382. PubMed ID: 34878755
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Effects of sodium-glucose cotransporter-2 inhibitors and aldosterone antagonists, in addition to renin-angiotensin system antagonists, on major adverse kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis.
    Yang S; Zhao L; Mi Y; He W
    Diabetes Obes Metab; 2022 Nov; 24(11):2159-2168. PubMed ID: 35712807
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Finerenone: A Potential Treatment for Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus.
    D'Marco L; Puchades MJ; Gandía L; Forquet C; Giménez-Civera E; Panizo N; Reque J; Juan-García I; Bermúdez V; Gorriz JL
    touchREV Endocrinol; 2021 Nov; 17(2):84-87. PubMed ID: 35118452
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.